NUCANA PLC-ADR (NCNA)
US67022C2052 - ADR
Taking everything into account, NCNA scores 1 out of 10 in our fundamental rating. NCNA was compared to 564 industry peers in the Biotechnology industry. NCNA has a bad profitability rating. Also its financial health evaluation is rather negative. NCNA does not seem to be growing, but still is valued expensively.
1. Profitability
1.1 Basic Checks
In the past year NCNA has reported negative net income.
NCNA had a negative operating cash flow in the past year.
In the past 5 years NCNA always reported negative net income.
NCNA had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
NCNA has a worse Return On Assets (-140.43%) than 84.49% of its industry peers.
NCNA's Return On Equity of -741.68% is on the low side compared to the rest of the industry. NCNA is outperformed by 81.46% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -140.43% | ||
| ROE | -741.68% | ||
| ROIC | N/A |
ROA(3y)-68.88%
ROA(5y)-53.12%
ROE(3y)-110.2%
ROE(5y)-79.05%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
NCNA does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
Compared to 1 year ago, NCNA has more shares outstanding
The number of shares outstanding for NCNA has been increased compared to 5 years ago.
NCNA has a worse debt/assets ratio than last year.
2.2 Solvency
Based on the Altman-Z score of -15.19, we must say that NCNA is in the distress zone and has some risk of bankruptcy.
NCNA has a worse Altman-Z score (-15.19) than 83.42% of its industry peers.
A Debt/Equity ratio of 0.04 indicates that NCNA is not too dependend on debt financing.
NCNA's Debt to Equity ratio of 0.04 is on the low side compared to the rest of the industry. NCNA is outperformed by 60.07% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.04 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -15.19 |
ROIC/WACCN/A
WACCN/A
2.3 Liquidity
NCNA has a Current Ratio of 1.08. This is a normal value and indicates that NCNA is financially healthy and should not expect problems in meeting its short term obligations.
NCNA's Current ratio of 1.08 is on the low side compared to the rest of the industry. NCNA is outperformed by 87.17% of its industry peers.
NCNA has a Quick Ratio of 1.08. This is a normal value and indicates that NCNA is financially healthy and should not expect problems in meeting its short term obligations.
The Quick ratio of NCNA (1.08) is worse than 84.85% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.08 | ||
| Quick Ratio | 1.08 |
3. Growth
3.1 Past
NCNA shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 17.46%, which is quite good.
EPS 1Y (TTM)17.46%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-20%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
3.2 Future
NCNA is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 24.99% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y13.3%
EPS Next 2Y19.49%
EPS Next 3Y23.99%
EPS Next 5Y24.99%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
4. Valuation
4.1 Price/Earnings Ratio
NCNA reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for NCNA. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A more expensive valuation may be justified as NCNA's earnings are expected to grow with 23.99% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y19.49%
EPS Next 3Y23.99%
5. Dividend
5.1 Amount
No dividends for NCNA!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
NUCANA PLC-ADR
NASDAQ:NCNA (11/4/2024, 8:25:53 PM)
After market: 1.61 +0.06 (+3.87%)1.55
+0.01 (+0.65%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap3.51M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -140.43% | ||
| ROE | -741.68% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.04 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 1.08 | ||
| Quick Ratio | 1.08 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
High Growth Momentum
Growth
EPS 1Y (TTM)17.46%
EPS 3YN/A
EPS 5Y
EPS Q2Q%
EPS Next Y13.3%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5Y
Sales Q2Q%
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y